On March 10, Medtronic announced its entry into a definitive agreement to acquire Scientia Vascular. The acquisition is valued at $550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments post-acquisition.
Scientia Vascular is a private company operating in Salt Lake City, Utah, with approximately 310 employees. The company has developed access products that enable simplicity and access for physicians treating complex neurovascular conditions.
Medtronic manufactures and sells device-based medical therapies worldwide, including spinal, cardiovascular and minimally invasive devices. For the fiscal year (FY) ending April 25, 2025, the company reported worldwide revenue of $33.54 billion, a 3.6% increase on a reported basis and a 4.9% increase on an organic basis compared with the previous fiscal year.
Scientia’s portfolio of guidewires and catheters can be seamlessly integrated with Medtronic’s existing suite of neurovascular products, strengthening the company’s ability to support physicians across the full procedural workflow.
This acquisition is expected to close in the first half of 2027, subject to regulatory approvals and satisfaction of other closing conditions. It is expected to be minimally dilutive to Medtronic adjusted EPS in FY 2027 and accretive thereafter.
This deal follows the February 2026 announcement of Medtronic’s acquisition of CathWorks, an Israel-based medical device company focused on applying its computational science platform to optimize coronary artery disease therapy decisions.
According to data captured in the LevinPro HC database, this marks the 22nd Medical Device transaction of 2026. There were 86 Medical Device deals announced during 2025, 87 announced in 2024 and 112 announced during 2023.
